Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xenetic Biosciences Inc XBIO

Healthcare Biotechnology
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the... see more

Recent & Breaking News (NDAQ:XBIO)

Xenetic Biosciences Commences Patient Enrollment in Phase 2 Study Evaluating XBIO-101 in Conjunction with Progestin Therapy for the Treatment of Endometrial Cancer

Business Wire June 26, 2017

Xenetic Biosciences Receives Program Update from Partner Shire’s Phase 1/2 Study Evaluating SHP656 in Development as a Long-acting Treatment for Hemophilia A

Business Wire May 22, 2017

Xenetic Biosciences Reports 2017 First Quarter Financial Results and Provides Business Update

Business Wire May 16, 2017

Xenetic Biosciences to Host 2017 First Quarter Update Conference Call

Business Wire May 9, 2017

Xenetic Biosciences Presents Case Study of PolyXen™ Platform Technology at the 13th Annual Protein Engineering Summit (PEGS) Boston

Business Wire May 1, 2017

Xenetic Biosciences’ PolyXen™ Platform Technology Accepted for Poster Presentation at the 13th Annual Protein Engineering Summit (PEGS) Boston

Business Wire April 20, 2017

Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA as Chief Financial Officer

Business Wire April 4, 2017

Xenetic Biosciences Reports 2016 Year End Financial Results and Provides Business Update

Business Wire April 3, 2017

Xenetic Biosciences, Inc. (Nasdaq: XBIO) to Ring The Nasdaq Stock Market Opening Bell

GlobeNewswire March 29, 2017

Xenetic Biosciences to Ring Nasdaq Stock Market Opening Bell on March 30, 2017

Business Wire March 29, 2017

Xenetic Biosciences Provides Update on Patent Portfolio Development

Business Wire March 27, 2017

Xenetic Biosciences to Present at the 29th Annual ROTH Conference

Business Wire March 9, 2017

Xenetic Biosciences Receives $3 Million Milestone Payment from Shire plc for PSA-Recombinant SHP656 in Development for Long-Acting Treatment for Hemophilia

Business Wire January 6, 2017

Xenetic Biosciences Appoints Curtis A. Lockshin, Ph.D. as Chief Scientific Officer

Business Wire January 4, 2017

Xenetic Biosciences to Present at Biotech Showcase 2017

Business Wire January 3, 2017

10 Biggest Mid-Day Gainers For Friday

Benzinga.com  December 30, 2016

Xenetic Biosciences Expands Management Team with Key Appointment of Jeffrey F. Eisenberg as Chief Operating Officer

Business Wire December 5, 2016

Xenetic Biosciences to Present at the LD Micro 2016 Annual Conference

Business Wire December 1, 2016

Xenetic Biosciences to Host Quarterly Update Conference Call and Webcast

Business Wire November 23, 2016

Xenetic Biosciences Appoints Edward J. Benz, Jr., M.D., Former Dana-Farber CEO, to its Board of Directors

Business Wire November 22, 2016